Nadia Peragine | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
NG2 molecule expression in acute lymphoblastic leukemia B cells: a flow-cytometric marker for the rapid identification of KMT2A gene rearrangements	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2024
Sialylation regulates migration in chronic lymphocytic leukemia	HAEMATOLOGICA	2023
Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia	CANCERS	2023
Neoplastic bone marrow invasion:rapid exclusion of hematological disease by flow cytometric routine panels	BLOOD CELLS, MOLECULES, & DISEASES	2023
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia	HAEMATOLOGICA	2022
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial	AMERICAN JOURNAL OF HEMATOLOGY	2022
Utility of Flow Cytometry Ascitic Fluid Analysis for Rapid Diagnosis of B-Cell Peritoneal Lymphomatosis	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2022
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall	BRITISH JOURNAL OF HAEMATOLOGY	2022
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response	LEUKEMIA & LYMPHOMA	2022
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab	HAEMATOLOGICA	2021
TH2/TH1 shift under Ibrutinib treatment in chronic lymphocytic leukemia	FRONTIERS IN ONCOLOGY	2021
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study	BLOOD	2021
Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab	BLOOD	2021
Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab	BLOOD	2021
COMPLEX KARYOTYPE IS ASSOCIATED WITH A LESS FAVORABLE OUTCOME AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114).	HemaSphere 2020; 4 (S1) p 290	2020
COMPLEX KARYOTYPE AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114)	Haematologica, 2020; 105(s2):s28	2020
ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia	BRITISH JOURNAL OF HAEMATOLOGY	2020
Atypical chronic myeloid leukemia in a patient with aplastic anemia	ACTA HAEMATOLOGICA	2019
Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients	ANNALS OF ONCOLOGY	2018
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.	BRITISH JOURNAL OF HAEMATOLOGY	2018